| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 41 | 2023 | 413 | 9.870 |
Why?
|
| Adenomatous Polyposis Coli | 17 | 2022 | 27 | 5.140 |
Why?
|
| Adenoma | 17 | 2023 | 89 | 4.200 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 9 | 2022 | 18 | 3.570 |
Why?
|
| Colonic Polyps | 9 | 2023 | 67 | 2.560 |
Why?
|
| Genetic Testing | 8 | 2022 | 71 | 2.240 |
Why?
|
| Puerto Rico | 23 | 2023 | 1352 | 2.000 |
Why?
|
| Adenocarcinoma | 7 | 2016 | 239 | 1.760 |
Why?
|
| Colonoscopy | 16 | 2023 | 98 | 1.710 |
Why?
|
| Humans | 100 | 2023 | 34853 | 1.490 |
Why?
|
| Colonic Neoplasms | 6 | 2023 | 181 | 1.430 |
Why?
|
| Stomach Neoplasms | 4 | 2022 | 192 | 1.380 |
Why?
|
| Helicobacter Infections | 4 | 2017 | 74 | 1.380 |
Why?
|
| Mutation | 9 | 2023 | 1023 | 1.360 |
Why?
|
| Middle Aged | 60 | 2023 | 9642 | 1.360 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 44 | 1.340 |
Why?
|
| Early Detection of Cancer | 7 | 2020 | 292 | 1.260 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2022 | 528 | 1.230 |
Why?
|
| Female | 70 | 2023 | 19873 | 1.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 790 | 1.170 |
Why?
|
| Male | 65 | 2023 | 18870 | 1.170 |
Why?
|
| Carcinoma | 4 | 2017 | 94 | 1.160 |
Why?
|
| DNA Mismatch Repair | 4 | 2020 | 24 | 1.140 |
Why?
|
| Aged | 44 | 2023 | 6448 | 1.120 |
Why?
|
| MutS Homolog 2 Protein | 6 | 2019 | 30 | 1.110 |
Why?
|
| Curcumin | 3 | 2018 | 66 | 0.960 |
Why?
|
| Mass Screening | 5 | 2022 | 427 | 0.950 |
Why?
|
| Helicobacter pylori | 4 | 2017 | 105 | 0.950 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 23 | 0.910 |
Why?
|
| Advisory Committees | 2 | 2020 | 28 | 0.880 |
Why?
|
| Occult Blood | 4 | 2016 | 25 | 0.830 |
Why?
|
| Insulin-Like Growth Factor II | 5 | 2011 | 22 | 0.820 |
Why?
|
| Neoplasms | 7 | 2020 | 1033 | 0.780 |
Why?
|
| Precancerous Conditions | 5 | 2015 | 81 | 0.770 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2018 | 9 | 0.770 |
Why?
|
| Colectomy | 3 | 2018 | 16 | 0.760 |
Why?
|
| Genomic Imprinting | 4 | 2011 | 35 | 0.750 |
Why?
|
| Career Choice | 2 | 2017 | 44 | 0.700 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 187 | 0.700 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2015 | 180 | 0.690 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 63 | 0.690 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 70 | 0.680 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2022 | 16 | 0.670 |
Why?
|
| Adult | 40 | 2023 | 11034 | 0.660 |
Why?
|
| Gastroenterology | 3 | 2017 | 8 | 0.650 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 14 | 0.650 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 756 | 0.640 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 336 | 0.640 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 232 | 0.630 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 107 | 0.620 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 2333 | 0.600 |
Why?
|
| DNA-Binding Proteins | 4 | 2019 | 522 | 0.590 |
Why?
|
| Gastritis, Atrophic | 1 | 2016 | 10 | 0.590 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2008 | 112 | 0.590 |
Why?
|
| Career Mobility | 1 | 2017 | 24 | 0.590 |
Why?
|
| Prevalence | 11 | 2023 | 1425 | 0.580 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 287 | 0.580 |
Why?
|
| Biomedical Research | 4 | 2019 | 371 | 0.580 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 15 | 0.580 |
Why?
|
| Health Education | 1 | 2019 | 304 | 0.570 |
Why?
|
| Public Health | 1 | 2020 | 348 | 0.570 |
Why?
|
| Risk Factors | 13 | 2018 | 3414 | 0.560 |
Why?
|
| Occupational Exposure | 1 | 2016 | 67 | 0.550 |
Why?
|
| Microsatellite Instability | 3 | 2023 | 43 | 0.550 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 35 | 0.550 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 9 | 0.540 |
Why?
|
| Digestive System Neoplasms | 1 | 2014 | 4 | 0.510 |
Why?
|
| Adenomatous Polyps | 3 | 2015 | 12 | 0.510 |
Why?
|
| Dietary Supplements | 3 | 2017 | 196 | 0.490 |
Why?
|
| DNA Glycosylases | 1 | 2013 | 16 | 0.480 |
Why?
|
| Interprofessional Relations | 1 | 2013 | 48 | 0.470 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 2561 | 0.470 |
Why?
|
| Case-Control Studies | 6 | 2020 | 1056 | 0.450 |
Why?
|
| Retrospective Studies | 11 | 2022 | 1961 | 0.450 |
Why?
|
| Mentors | 1 | 2013 | 111 | 0.450 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 446 | 0.430 |
Why?
|
| Physicians | 1 | 2013 | 148 | 0.420 |
Why?
|
| Registries | 7 | 2019 | 330 | 0.420 |
Why?
|
| Barrett Esophagus | 4 | 2014 | 29 | 0.410 |
Why?
|
| Smoking | 3 | 2016 | 903 | 0.410 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2009 | 26 | 0.400 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 64 | 0.400 |
Why?
|
| Biopsy | 3 | 2014 | 151 | 0.400 |
Why?
|
| Vitamins | 2 | 2015 | 91 | 0.390 |
Why?
|
| DNA Methylation | 3 | 2023 | 301 | 0.390 |
Why?
|
| Young Adult | 11 | 2019 | 4012 | 0.370 |
Why?
|
| United States | 9 | 2022 | 3894 | 0.370 |
Why?
|
| Calcium, Dietary | 1 | 2010 | 83 | 0.360 |
Why?
|
| Prognosis | 4 | 2018 | 707 | 0.360 |
Why?
|
| Barium Sulfate | 1 | 2009 | 2 | 0.350 |
Why?
|
| Enema | 1 | 2009 | 9 | 0.350 |
Why?
|
| Contrast Media | 2 | 2009 | 95 | 0.350 |
Why?
|
| Quercetin | 2 | 2006 | 41 | 0.340 |
Why?
|
| Obesity | 1 | 2016 | 965 | 0.330 |
Why?
|
| Duodenal Neoplasms | 2 | 2022 | 5 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 592 | 0.310 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2007 | 14 | 0.300 |
Why?
|
| Colon | 4 | 2017 | 98 | 0.300 |
Why?
|
| Treatment Outcome | 7 | 2018 | 1349 | 0.300 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 424 | 0.290 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2006 | 1 | 0.290 |
Why?
|
| Enteral Nutrition | 1 | 2006 | 16 | 0.280 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 41 | 0.280 |
Why?
|
| Proton Pump Inhibitors | 2 | 2016 | 9 | 0.260 |
Why?
|
| Minority Groups | 2 | 2020 | 537 | 0.260 |
Why?
|
| Time Factors | 7 | 2020 | 1681 | 0.250 |
Why?
|
| Adolescent | 9 | 2018 | 5035 | 0.250 |
Why?
|
| Double-Blind Method | 4 | 2018 | 269 | 0.250 |
Why?
|
| Risk Assessment | 5 | 2018 | 727 | 0.240 |
Why?
|
| Age Factors | 4 | 2017 | 1007 | 0.240 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 555 | 0.230 |
Why?
|
| Gene Amplification | 1 | 2023 | 24 | 0.230 |
Why?
|
| Vaccines, DNA | 1 | 2023 | 23 | 0.230 |
Why?
|
| Incidence | 4 | 2022 | 882 | 0.230 |
Why?
|
| Muir-Torre Syndrome | 2 | 2015 | 2 | 0.230 |
Why?
|
| Antioxidants | 1 | 2006 | 386 | 0.220 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 39 | 0.220 |
Why?
|
| Proteins | 1 | 2005 | 352 | 0.220 |
Why?
|
| Sex Factors | 3 | 2017 | 859 | 0.220 |
Why?
|
| Sulindac | 1 | 2002 | 7 | 0.220 |
Why?
|
| Disease Progression | 5 | 2017 | 580 | 0.220 |
Why?
|
| Cost of Illness | 2 | 2014 | 79 | 0.210 |
Why?
|
| Hepatitis C | 1 | 2023 | 120 | 0.210 |
Why?
|
| Tumor Burden | 2 | 2018 | 79 | 0.200 |
Why?
|
| Pedigree | 2 | 2018 | 64 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 147 | 0.190 |
Why?
|
| Calcium | 3 | 2017 | 445 | 0.190 |
Why?
|
| GTP Phosphohydrolases | 1 | 2020 | 29 | 0.190 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 195 | 0.190 |
Why?
|
| Patient Selection | 2 | 2018 | 154 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 964 | 0.180 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 859 | 0.180 |
Why?
|
| Metaplasia | 2 | 2016 | 34 | 0.180 |
Why?
|
| Cholecystitis | 3 | 2003 | 4 | 0.180 |
Why?
|
| Indians, Central American | 1 | 2019 | 2 | 0.180 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 51 | 0.170 |
Why?
|
| Heredity | 1 | 2018 | 5 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2010 | 81 | 0.170 |
Why?
|
| Behavioral Research | 1 | 2019 | 37 | 0.170 |
Why?
|
| Alcohol Drinking | 3 | 2016 | 490 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 14 | 0.170 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 1003 | 0.170 |
Why?
|
| Minority Health | 1 | 2019 | 81 | 0.170 |
Why?
|
| Schools, Medical | 1 | 2020 | 192 | 0.160 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 217 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2018 | 69 | 0.160 |
Why?
|
| Intestinal Polyps | 2 | 2010 | 4 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 32 | 0.160 |
Why?
|
| Seroepidemiologic Studies | 1 | 2017 | 67 | 0.160 |
Why?
|
| Obesity, Morbid | 2 | 2008 | 17 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 269 | 0.160 |
Why?
|
| Health Status Disparities | 2 | 2020 | 583 | 0.150 |
Why?
|
| Esophagus | 2 | 2014 | 41 | 0.150 |
Why?
|
| Amoxicillin | 1 | 2016 | 1 | 0.150 |
Why?
|
| DNA Repair Enzymes | 1 | 2017 | 20 | 0.150 |
Why?
|
| Clarithromycin | 1 | 2016 | 8 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2018 | 1353 | 0.150 |
Why?
|
| Metronidazole | 1 | 2016 | 13 | 0.150 |
Why?
|
| Workload | 1 | 2017 | 22 | 0.150 |
Why?
|
| Latin America | 1 | 2016 | 41 | 0.150 |
Why?
|
| Vitamin D | 2 | 2017 | 176 | 0.150 |
Why?
|
| Insurance, Health | 2 | 2016 | 120 | 0.150 |
Why?
|
| Gastrectomy | 1 | 2016 | 9 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 54 | 0.150 |
Why?
|
| Insurance Coverage | 2 | 2014 | 99 | 0.150 |
Why?
|
| Health Planning | 1 | 2016 | 16 | 0.150 |
Why?
|
| Membrane Proteins | 1 | 2020 | 486 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 106 | 0.140 |
Why?
|
| Government Programs | 1 | 2016 | 28 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 28 | 0.140 |
Why?
|
| Sigmoidoscopy | 3 | 2016 | 8 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2016 | 212 | 0.140 |
Why?
|
| Rural Population | 1 | 2017 | 253 | 0.140 |
Why?
|
| Hospitals, University | 1 | 2015 | 38 | 0.140 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 20 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2016 | 91 | 0.140 |
Why?
|
| Caribbean Region | 1 | 2015 | 63 | 0.140 |
Why?
|
| Phenotype | 3 | 2013 | 650 | 0.130 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2006 | 6 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 282 | 0.130 |
Why?
|
| Feces | 1 | 2015 | 110 | 0.130 |
Why?
|
| Decision Making | 1 | 2016 | 189 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2017 | 517 | 0.120 |
Why?
|
| Polyps | 2 | 2004 | 9 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 605 | 0.120 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2003 | 3 | 0.120 |
Why?
|
| Syndrome | 1 | 2013 | 72 | 0.120 |
Why?
|
| Metformin | 1 | 2014 | 64 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 570 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 355 | 0.120 |
Why?
|
| Genotype | 2 | 2013 | 641 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 124 | 0.110 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2012 | 28 | 0.110 |
Why?
|
| Dinoprostone | 1 | 2012 | 57 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 105 | 0.110 |
Why?
|
| Family | 1 | 2013 | 162 | 0.110 |
Why?
|
| Aspirin | 1 | 2012 | 45 | 0.110 |
Why?
|
| Radiography | 2 | 2009 | 75 | 0.110 |
Why?
|
| Mouth Mucosa | 1 | 2011 | 33 | 0.100 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 89 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 157 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 166 | 0.100 |
Why?
|
| Diet Records | 1 | 2010 | 56 | 0.100 |
Why?
|
| Recurrence | 2 | 2012 | 125 | 0.100 |
Why?
|
| ras Proteins | 1 | 2010 | 49 | 0.100 |
Why?
|
| Public Policy | 1 | 2010 | 31 | 0.090 |
Why?
|
| Child | 4 | 2013 | 2875 | 0.090 |
Why?
|
| Lymphocytes | 3 | 2011 | 116 | 0.090 |
Why?
|
| Diet | 1 | 2016 | 747 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 79 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 386 | 0.090 |
Why?
|
| North America | 2 | 2017 | 60 | 0.090 |
Why?
|
| Cholelithiasis | 3 | 2003 | 4 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 13 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 375 | 0.090 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2008 | 1 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 211 | 0.090 |
Why?
|
| Duodenoscopy | 2 | 2010 | 2 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1149 | 0.090 |
Why?
|
| Genomic Instability | 1 | 2009 | 34 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2009 | 67 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 229 | 0.090 |
Why?
|
| DNA Repair | 1 | 2010 | 181 | 0.080 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 14 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2012 | 775 | 0.080 |
Why?
|
| Mesalamine | 1 | 2008 | 2 | 0.080 |
Why?
|
| Gastric Fundus | 2 | 2004 | 3 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 445 | 0.080 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2007 | 5 | 0.080 |
Why?
|
| Antibodies, Fungal | 1 | 2007 | 23 | 0.080 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2006 | 4 | 0.070 |
Why?
|
| Mitochondria | 1 | 2010 | 454 | 0.070 |
Why?
|
| Gastric Bypass | 1 | 2006 | 14 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 198 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 85 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 233 | 0.070 |
Why?
|
| Jejunostomy | 1 | 2006 | 2 | 0.070 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 2 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2007 | 55 | 0.070 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2007 | 193 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2005 | 62 | 0.070 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 13 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 781 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2006 | 206 | 0.070 |
Why?
|
| Guideline Adherence | 2 | 2017 | 82 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2015 | 1422 | 0.060 |
Why?
|
| Education, Medical | 1 | 2006 | 97 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 85 | 0.060 |
Why?
|
| CpG Islands | 1 | 2004 | 91 | 0.060 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2003 | 1 | 0.060 |
Why?
|
| Dietary Fiber | 1 | 2004 | 42 | 0.060 |
Why?
|
| Duodenal Diseases | 1 | 2003 | 3 | 0.060 |
Why?
|
| Sphincter of Oddi | 1 | 2003 | 1 | 0.060 |
Why?
|
| Folic Acid | 1 | 2004 | 46 | 0.060 |
Why?
|
| Nitroprusside | 1 | 2003 | 13 | 0.060 |
Why?
|
| Curriculum | 1 | 2006 | 237 | 0.060 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 18 | 0.060 |
Why?
|
| Gastrointestinal Motility | 1 | 2003 | 18 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2003 | 21 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 18 | 0.060 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2003 | 2 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2004 | 115 | 0.060 |
Why?
|
| Cryotherapy | 1 | 2003 | 10 | 0.060 |
Why?
|
| Vaccines, Subunit | 1 | 2023 | 30 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 2003 | 6 | 0.060 |
Why?
|
| Pancreatitis | 1 | 2003 | 16 | 0.060 |
Why?
|
| Pancreas | 1 | 2003 | 32 | 0.060 |
Why?
|
| Pain, Postoperative | 1 | 2003 | 22 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2023 | 46 | 0.060 |
Why?
|
| Hepacivirus | 1 | 2023 | 59 | 0.060 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2023 | 45 | 0.060 |
Why?
|
| Duodenum | 1 | 2022 | 12 | 0.050 |
Why?
|
| Remission Induction | 2 | 2016 | 18 | 0.050 |
Why?
|
| Rectum | 1 | 2002 | 22 | 0.050 |
Why?
|
| Risk | 2 | 2015 | 256 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2004 | 207 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2002 | 31 | 0.050 |
Why?
|
| Selenium | 1 | 2004 | 144 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 114 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 97 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2002 | 167 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 271 | 0.050 |
Why?
|
| Placebos | 2 | 2014 | 38 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 133 | 0.050 |
Why?
|
| DNA | 1 | 2023 | 549 | 0.050 |
Why?
|
| South America | 1 | 2019 | 16 | 0.050 |
Why?
|
| HCT116 Cells | 2 | 2010 | 34 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 638 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2018 | 1 | 0.040 |
Why?
|
| Fanconi Anemia | 1 | 2018 | 12 | 0.040 |
Why?
|
| Gastric Mucosa | 2 | 2011 | 50 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2018 | 40 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 37 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 133 | 0.040 |
Why?
|
| Maryland | 2 | 2008 | 53 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 158 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2016 | 26 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2017 | 65 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 92 | 0.040 |
Why?
|
| District of Columbia | 1 | 2015 | 68 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2003 | 469 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 65 | 0.030 |
Why?
|
| Urban Health | 1 | 2015 | 86 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 213 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 225 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2014 | 3 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2014 | 9 | 0.030 |
Why?
|
| Health Care Reform | 1 | 2014 | 31 | 0.030 |
Why?
|
| Habits | 1 | 2013 | 7 | 0.030 |
Why?
|
| Survival Rate | 1 | 2014 | 310 | 0.030 |
Why?
|
| Intestinal Mucosa | 2 | 2005 | 115 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2013 | 136 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 2128 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 894 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2012 | 5 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 188 | 0.030 |
Why?
|
| Insulin | 1 | 2014 | 224 | 0.030 |
Why?
|
| Educational Status | 1 | 2013 | 295 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2010 | 38 | 0.020 |
Why?
|
| Health Promotion | 1 | 2016 | 588 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 98 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2003 | 628 | 0.020 |
Why?
|
| Anemia | 1 | 2010 | 45 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 420 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 168 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 180 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 531 | 0.020 |
Why?
|
| Veterans | 1 | 2010 | 115 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 18 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 17 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 32 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 63 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2009 | 49 | 0.020 |
Why?
|
| Colon, Descending | 1 | 2008 | 1 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 834 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 416 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2008 | 40 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2008 | 59 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 606 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 55 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2008 | 32 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 242 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 122 | 0.020 |
Why?
|
| Diatrizoate Meglumine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 600 | 0.020 |
Why?
|
| Florida | 1 | 2008 | 358 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 229 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2005 | 7 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2005 | 3 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 30 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2005 | 46 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 284 | 0.020 |
Why?
|
| Cadaver | 1 | 2005 | 41 | 0.020 |
Why?
|
| Linear Models | 1 | 2006 | 253 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2006 | 115 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2005 | 43 | 0.020 |
Why?
|
| Menstruation Disturbances | 1 | 2005 | 3 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2005 | 25 | 0.020 |
Why?
|
| Flavonoids | 1 | 2005 | 78 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 465 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2006 | 124 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2004 | 9 | 0.020 |
Why?
|
| DNA Primers | 1 | 2004 | 269 | 0.020 |
Why?
|
| Manometry | 1 | 2003 | 7 | 0.020 |
Why?
|
| Injections | 1 | 2003 | 35 | 0.020 |
Why?
|
| Digestive System Diseases | 1 | 2003 | 4 | 0.020 |
Why?
|
| Cholestasis | 1 | 2003 | 9 | 0.020 |
Why?
|
| Sclerosis | 1 | 2003 | 6 | 0.010 |
Why?
|
| Pancreatic Diseases | 1 | 2003 | 5 | 0.010 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2003 | 1 | 0.010 |
Why?
|
| Proctitis | 1 | 2003 | 2 | 0.010 |
Why?
|
| Arteriovenous Malformations | 1 | 2003 | 2 | 0.010 |
Why?
|
| Gastritis | 1 | 2003 | 11 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 430 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 182 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2003 | 23 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 196 | 0.010 |
Why?
|
| Family Health | 1 | 2003 | 47 | 0.010 |
Why?
|
| Genes, APC | 1 | 2002 | 14 | 0.010 |
Why?
|
| Point Mutation | 1 | 2002 | 88 | 0.010 |
Why?
|
| beta Catenin | 1 | 2002 | 46 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 75 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 151 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 142 | 0.010 |
Why?
|
| California | 1 | 2002 | 436 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 608 | 0.010 |
Why?
|
| Animals | 2 | 2008 | 14307 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 639 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 5668 | 0.010 |
Why?
|